<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">fcmedicine</journal-id><journal-title-group><journal-title xml:lang="ru">Фундаментальная и клиническая медицина</journal-title><trans-title-group xml:lang="en"><trans-title>Fundamental and Clinical Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2500-0764</issn><issn pub-type="epub">2542-0941</issn><publisher><publisher-name>КемГМУ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.23946/2500-0764-2024-9-2-66-71</article-id><article-id custom-type="elpub" pub-id-type="custom">fcmedicine-863</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Прогноз развития бессимптомного каротидного атеросклероза</article-title><trans-title-group xml:lang="en"><trans-title>Cholesterol of Low-Density Lipoprotein-Containing Circulating Immune Complexes Improves Prognosis of Asymptomatic Carotid Atherosclerosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3318-4681</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Орехов</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Orekhov</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Орехов Александр Николаевич, доктор биологических наук, профессор, руководитель лаборатории ангиопатологии отдела общей патологии</p><p>125315, г. Москва, ул. Балтийская, д. 8 </p></bio><bio xml:lang="en"><p>Prof. Alexander N. Orekhov, DSc, Professor, Head of the Laboratory of Angiopathology, Department of General Pathology</p><p>8, Baltiyskaya Street, Moscow, 125315 </p></bio><email xlink:type="simple">alexandernikolaevichorekhov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-1339-2878</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Орехов</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Orekhov</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Орехов Николай Александрович, лаборант-исследователь лаборатории ангиопатологии отдела общей патологии</p><p>125315, г. Москва, ул. Балтийская, д. 8 </p></bio><bio xml:lang="en"><p>Mr. Nikolay A. Orekhov, Assistant Researcher, Laboratory of Angiopathology, Department of General Pathology</p><p>8, Baltiyskaya Street, Moscow, 125315 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4512-4413</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Омельченко</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Omelchenko</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Омельченко Андрей Владимирович, кандидат биологических наук, старший научный сотрудник лаборатории ангиопатологии отдела общей патологии</p><p>125315, г. Москва, ул. Балтийская, д. 8 </p></bio><bio xml:lang="en"><p>Dr. Andrey V. Omelchenko, PhD, Senior Researcher, Laboratory of Angiopathology, Department of General Pathology</p><p>8, Baltiyskaya Street, Moscow, 125315 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0978-6444</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Собенин</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sobenin</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Собенин Игорь Александрович, доктор медицинских наук, ведущий научный сотрудник лаборатории ангиопатологии отдела общей патологии</p><p>125315, Россия, г. Москва, ул. Балтийская, д. 8 </p></bio><bio xml:lang="en"><p>Dr. Igor A. Sobenin, MD, DSc, Leading Researcher, Laboratory of Angiopathology, Department of General Pathology</p><p>8, Baltiyskaya Street, Moscow, 125315 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт общей патологии и патофизиологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of General Pathology and Pathophysiology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>21</day><month>06</month><year>2024</year></pub-date><volume>9</volume><issue>2</issue><fpage>66</fpage><lpage>71</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Орехов А.Н., Орехов Н.А., Омельченко А.В., Собенин И.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Орехов А.Н., Орехов Н.А., Омельченко А.В., Собенин И.А.</copyright-holder><copyright-holder xml:lang="en">Orekhov A.N., Orekhov N.A., Omelchenko A.V., Sobenin I.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://fcm.kemsmu.ru/jour/article/view/863">https://fcm.kemsmu.ru/jour/article/view/863</self-uri><abstract><sec><title>Цель</title><p>Цель. Ранее в крови пациентов с атеросклерозом были обнаружены циркулирующие иммунные комплексы, содержащие липопротеины низкой плотности (ЛНП-ЦИК). Была выявлена высокая диагностическая и прогностическая значимость уровня холестерина в ЛНП-ЦИК (Хол-ЦИК) в отношении развития бессимптомного атеросклероза. Целью данной работы была попытка улучшения прогностической значимости Хол-ЦИК путем комбинирования этого маркера с другими показателями.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Были использованы данные исследования, в которое был включён 101 мужчина с бессимптомным каротидным атеросклерозом. На протяжении 1 года у участников исследования ежеквартально оценивали клинические и биохимические показатели, включая Хол-ЦИК и толщину интима-медиального слоя сонной артерии (ТИМС).</p></sec><sec><title>Результаты</title><p>Результаты. Комбинация с возрастом повышала прогностическую значимость Хол-ЦИК с 63,5% до 78,3%, что превышало таковую у ХолЛНП и Хол-ЦИК по отдельности. При этом возраст не улучшал прогностическую значимость других липидных параметров. Таким образом, было установлено, что Хол-ЦИК обладает более высокой прогностической значимостью, чем другие липидные параметры.</p></sec><sec><title>Заключение</title><p>Заключение. Сочетание Хол-ЦИК и возраста пациентов может быть использовано для прогнозирования увеличения толщины ТИМС по отношению к начальному уровню.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. Previously, low-density lipoprotein-containing circulating immune complexes (LDL-CIC) were found in the blood of atherosclerotic patients. High diagnostic and prognostic significance of cholesterol level in LDL-CIC (Chol-CIC) in relation to the development of asymptomatic atherosclerosis suggested its clinical utility. Here we attempted to improve the prognostic value of CholCIC by combining this marker with other features.</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods. The study included 101 male patients with asymptomatic carotid atherosclerosis. During 1 year, we carried out quarterly measurements of clinical and biochemical features including Chol-CIC and intima-media thickness (IMT).</p></sec><sec><title>Results</title><p>Results. Combination with age increased the prognostic significance of Chol-CIC from 63.5% to 78.3% that exceeded those of low-density lipoprotein cholesterol (LDL-C) and Chol-CIC alone. Age did not improve prognostic significance of other lipid parameters. Therefore, Chol-CIC had higher prognostic significance in comparison to other lipid profile parameters.</p></sec><sec><title>Conclusion</title><p>Conclusion. Combination of Chol-CIC and patient age may be used for the prognosis of increasing intima-media thickness.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>атеросклероз</kwd><kwd>диагностическая значимость</kwd><kwd>липопротеины низкой плотности</kwd><kwd>прогностическая значимость</kwd><kwd>циркулирующие иммунные комплексы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atherosclerosis</kwd><kwd>diagnostic significance</kwd><kwd>low-density lipoprotein cholesterol</kwd><kwd>prognostic significance</kwd><kwd>circulating immune complexes</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена при поддержке Российского научного фонда (грант № 23-65-10014). Публикация размещена при участии Балтийского федерального университета им. И. Канта.</funding-statement><funding-statement xml:lang="en">This research was financially supported by Russian Science Foundation (grant № 23-65-10014). The publication has been supported by Immanuel Kant Baltic Federal University</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Тертов В.В., Качарава А.Г., Саидян Х.С., Серебренников С.Г., Лякишев А.А., Козлов С.Г., Грацианский Н.А., Рогова Е.М., Бочарова О.И., Орехов А.Н. Холестеринсодержащие циркулирующие иммунные комплексы - компонент сыворотки крови больных ишемической болезнью сердца, обусловливающий её атерогенность // Кардиология. 1989;29(8): 35-38.</mixed-citation><mixed-citation xml:lang="en">Tertov VV, Kacharava AG, Saidyan KhS, Serebrennikov SG, Lyakishev AA, Kozlov SG, Gratsianskiy NA, Rogova EM, Bocharova OI, Orekhov AN. Cholesterol-containing circulating immune complexes: an atherogenic component in serum of patients with coronary artery disease // Kardiologiia. 1989;29(8):35-38.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Sobenin IA, Orekhova VA, Melnichenko AА, Bobryshev YV, Orekhov AN. Low density lipoprotein-containing circulating immune complexes have better prognostic value in carotid intima-media thickness progression than other lipid parameters. Int. J. Cardiol. 2013;166(3):747-748. doi: 10.1016/j.ijcard.2012.09.175..</mixed-citation><mixed-citation xml:lang="en">Sobenin IA, Orekhova VA, Melnichenko AА, Bobryshev YV, Orekhov AN. Low density lipoprotein-containing circulating immune complexes have better prognostic value in carotid intima-media thickness progression than other lipid parameters. Int. J. Cardiol. 2013;166(3):747-748. doi: 10.1016/j.ijcard.2012.09.175..</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Orekhov AN, Kalenich OS, Tertov VV, Perova NV, Novikov IyD, Lyakishev AA, Deev AD, Ruda MYa. Diagnostic value of immune cholesterol as a marker for atherosclerosis. J. Cardiovasc. Risk. 1995;2(5):459-466. doi: 10.1177/174182679500200511.</mixed-citation><mixed-citation xml:lang="en">Orekhov AN, Kalenich OS, Tertov VV, Perova NV, Novikov IyD, Lyakishev AA, Deev AD, Ruda MYa. Diagnostic value of immune cholesterol as a marker for atherosclerosis. J. Cardiovasc. Risk. 1995;2(5):459-466. doi: 10.1177/174182679500200511.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Orekhov AN, Sobenin IA, Korneev NV, Kirichenko TV, Myasoedova VA, Melnichenko AA, Balcells M, Edelman ER, Bobryshev YV. Antiatherosclerotic therapy based on botanicals. Recent Pat. Cardiovasc. Drug Discov. 2013;8(1):56-66. doi: 10.2174/18722083113079990008.</mixed-citation><mixed-citation xml:lang="en">Orekhov AN, Sobenin IA, Korneev NV, Kirichenko TV, Myasoedova VA, Melnichenko AA, Balcells M, Edelman ER, Bobryshev YV. Antiatherosclerotic therapy based on botanicals. Recent Pat. Cardiovasc. Drug Discov. 2013;8(1):56-66. doi: 10.2174/18722083113079990008.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Sobenin IA, Karagodin VP, Melnichenko AC, Bobryshev YV, Orekhov AN. Diagnostic and prognostic value of low density lipoproteincontaining circulating immune complexes in atherosclerosis. J. Clin. Immunol. 2013;33(2):489-495. doi: 10.1007/s10875-012-9819-4.</mixed-citation><mixed-citation xml:lang="en">Sobenin IA, Karagodin VP, Melnichenko AC, Bobryshev YV, Orekhov AN. Diagnostic and prognostic value of low density lipoproteincontaining circulating immune complexes in atherosclerosis. J. Clin. Immunol. 2013;33(2):489-495. doi: 10.1007/s10875-012-9819-4.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Tertov VV, Orekhov AN, Sayadyan KS, Serebrennikov SG, Kacharava AG, Lyakishev AA, Smirnov VN. Correlation between cholesterol content in circulating immune complexes and atherogenic properties of CHD patients’ serum manifested in cell culture. Atherosclerosis. 1990;81(3):183-189. doi: 10.1016/0021-9150(90)90065-q.</mixed-citation><mixed-citation xml:lang="en">Tertov VV, Orekhov AN, Sayadyan KS, Serebrennikov SG, Kacharava AG, Lyakishev AA, Smirnov VN. Correlation between cholesterol content in circulating immune complexes and atherogenic properties of CHD patients’ serum manifested in cell culture. Atherosclerosis. 1990;81(3):183-189. doi: 10.1016/0021-9150(90)90065-q.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Orekhov AN, Tertov VV, Kabakov AE, Adamova IYu, Pokrovsky SN, Smirnov VN. Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foam cell formation. Arterioscler. Thromb. 1991;11(2):316-326. doi: 10.1161/01.atv.11.2.316.</mixed-citation><mixed-citation xml:lang="en">Orekhov AN, Tertov VV, Kabakov AE, Adamova IYu, Pokrovsky SN, Smirnov VN. Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foam cell formation. Arterioscler. Thromb. 1991;11(2):316-326. doi: 10.1161/01.atv.11.2.316.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lopes-Virella MF, Virella G. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. J. Atheroscler. Thromb. 2013;20(10):743-754. doi: 10.5551/jat.19281.</mixed-citation><mixed-citation xml:lang="en">Lopes-Virella MF, Virella G. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. J. Atheroscler. Thromb. 2013;20(10):743-754. doi: 10.5551/jat.19281.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Virella G, Wilson K, Elkes J, Hammad SM, Rajab HA, Li Y, Chassereau C, Huang Y, Lopes-Virella M. Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages. Clin. Immunol. 2018;187:1-9. doi: 10.1016/j.clim.2017.06.010.</mixed-citation><mixed-citation xml:lang="en">Virella G, Wilson K, Elkes J, Hammad SM, Rajab HA, Li Y, Chassereau C, Huang Y, Lopes-Virella M. Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages. Clin. Immunol. 2018;187:1-9. doi: 10.1016/j.clim.2017.06.010.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Rhoads JP, Lukens JR, Wilhelm AJ, Moore JL, Mendez-Fernandez Y, Kanneganti TD, Major AS. Oxidized low-density lipoprotein immune complex priming of the Nlrp3 inflammasome involves TLR and FcγR cooperation and is dependent on CARD9. J. Immunol. 2017;198(5):2105-2114. doi: 10.4049/jimmunol.1601563.</mixed-citation><mixed-citation xml:lang="en">Rhoads JP, Lukens JR, Wilhelm AJ, Moore JL, Mendez-Fernandez Y, Kanneganti TD, Major AS. Oxidized low-density lipoprotein immune complex priming of the Nlrp3 inflammasome involves TLR and FcγR cooperation and is dependent on CARD9. J. Immunol. 2017;198(5):2105-2114. doi: 10.4049/jimmunol.1601563.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lopes-Virella MF, Hunt KJ, Baker NL, Lachin J, Nathan DM, VirellaG; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes. 2011;60(2):582-589. doi: 10.2337/db10-0915.</mixed-citation><mixed-citation xml:lang="en">Lopes-Virella MF, Hunt KJ, Baker NL, Lachin J, Nathan DM, Virella G; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes. 2011;60(2):582-589. doi: 10.2337/db10-0915.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Hunt KJ, Baker N, Cleary P, Backlund JY, Lyons T, Jenkins A, Virella G, Lopes-Virella MF; DCCT/EDIC Research Group. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes. Atherosclerosis. 2013;231(2):315-22. doi: 10.1016/j.atherosclerosis.2013.09.027.</mixed-citation><mixed-citation xml:lang="en">Hunt KJ, Baker N, Cleary P, Backlund JY, Lyons T, Jenkins A, Virella G, Lopes-Virella MF; DCCT/EDIC Research Group. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes. Atherosclerosis. 2013;231(2):315-22. doi: 10.1016/j.atherosclerosis.2013.09.027.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lopes-Virella MF, Baker NL, Hunt KJ, Lachin J, Nathan D, Virella G; DCCT/ EDIC Research Group. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis. 2011;214(2):462-7. doi: 10.1016/j.atherosclerosis.2010.11.012.</mixed-citation><mixed-citation xml:lang="en">Lopes-Virella MF, Baker NL, Hunt KJ, Lachin J, Nathan D, Virella G; DCCT/ EDIC Research Group. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis. 2011;214(2):462-7. doi: 10.1016/j.atherosclerosis.2010.11.012.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hartley A, Pradeep M, Van den Berg V, Khan AHA, Shah HA, Allaf M, Chow A, Caga-Anan M, Shalhoub J, Koenig W, Fisher M, Haskard DO, Khamis RY. Depletion of homeostatic antibodies against malondialdehyde-modified low-density lipoprotein correlates with adverse events in major vascular surgery. Antioxidants (Basel). 2022;11(2):271. doi: 10.3390/antiox11020271.</mixed-citation><mixed-citation xml:lang="en">Hartley A, Pradeep M, Van den Berg V, Khan AHA, Shah HA, Allaf M, Chow A, Caga-Anan M, Shalhoub J, Koenig W, Fisher M, Haskard DO, Khamis RY. Depletion of homeostatic antibodies against malondialdehyde-modified low-density lipoprotein correlates with adverse events in major vascular surgery. Antioxidants (Basel). 2022;11(2):271. doi: 10.3390/antiox11020271.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Cavalcante MF, Adorne MD, Turato WM, Kemmerer M, Uchiyama MK, Asbahr ACC, Alves ACS, Farsky SHP, Drewes C, Spatti MC, Kazuma SM, Boss M, Guterres SS, Araki K, Brüne B, Namgaladze D, Pohlmann AR, Abdalla DSP. scFv-Anti-LDL(-)-metal-complex multi-wall functionalized-nanocapsules as a promising tool for the prevention of atherosclerosis progression. Front Med (Lausanne). 2021;8:652137. doi: 10.3389/fmed.2021.652137.</mixed-citation><mixed-citation xml:lang="en">Cavalcante MF, Adorne MD, Turato WM, Kemmerer M, Uchiyama MK, Asbahr ACC, Alves ACS, Farsky SHP, Drewes C, Spatti MC, Kazuma SM, Boss M, Guterres SS, Araki K, Brüne B, Namgaladze D, Pohlmann AR, Abdalla DSP. scFv-Anti-LDL(-)-metal-complex multi-wall functionalized-nanocapsules as a promising tool for the prevention of atherosclerosis progression. Front Med (Lausanne). 2021;8:652137. doi: 10.3389/fmed.2021.652137.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
